Physician profile
James K Walker
NPI 1265412472
$1,653.05
in general payments reported to CMS, 2019-2025
25 companies · $32.65 in 2025
The $32.65 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $35.74 · 2020: $80.82 · 2021: $627 · 2022: $519 · 2023: $135 · 2024: $223 · 2025: $32.65.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $391.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $391.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $298.97 | 2021-2025 | Vraylar |
| Novo Nordisk INC | $192.05 | 2021-2023 | Wegovy |
| Astrazeneca Pharmaceuticals Lp | $153.88 | 2020-2024 | Farxiga |
| Janssen Pharmaceuticals, INC | $146.87 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $124.27 | 2021-2024 | |
| Dexcom, INC. | $115.14 | 2021-2023 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $110.41 | 2021-2024 | |
| Glaxosmithkline, LLC. | $53.19 | 2021-2022 | |
| Amarin Pharma, INC. | $50.49 | 2020-2022 | |
| Lilly USA, LLC | $44.37 | 2020-2022 | |
| Abbott Laboratories | $38.93 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.52 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $36.74 | 2021 | |
| Ironshore Pharmaceuticals INC. | $35.66 | 2022 | |
| Amgen INC. | $31.35 | 2022-2024 | Otezla, Repatha |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $28.74 | 2023-2024 | |
| Xeris Pharmaceuticals, INC. | $24.74 | 2023 | Keveyis |
| Tactile Systems Technology INC | $22.37 | 2024 | Entre Plus, Flexitouch Plus |
| Baxter Healthcare | $18.43 | 2024 | Hillrom - Vest System Model 105 Home Care |
| Almatica Pharma LLC | $17.87 | 2021 | |
| Smith+Nephew, INC. | $15.76 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $14.29 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $13.95 | 2021 | |
| Sumitomo Pharma America, INC. | $13.93 | 2023 | Gemtesa |
| Eisai INC. | $12.13 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Walker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.